Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone651-259-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$248.02 million
Profitability
Miscellaneous
Employees652
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) announced its earnings results on Wednesday, February, 5th. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.07. The medical device company had revenue of $68.33 million for the quarter, compared to the consensus estimate of $67.90 million. Cardiovascular Systems had a negative return on equity of 4.90% and a negative net margin of 2.66%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What guidance has Cardiovascular Systems issued on next quarter's earnings?
Cardiovascular Systems updated its FY 2020
After-Hours earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $280-283 million, compared to the consensus revenue estimate of $280.7 million.
What price target have analysts set for CSII?
5 brokers have issued 1-year price targets for Cardiovascular Systems' shares. Their forecasts range from $42.00 to $60.00. On average, they expect Cardiovascular Systems' stock price to reach $51.25 in the next twelve months. This suggests a possible upside of 32.5% from the stock's current price. View Analyst Price Targets for Cardiovascular Systems.
What is the consensus analysts' recommendation for Cardiovascular Systems?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems saw operating loss and margin contraction during the first-quarter fiscal 2020. Rising operating expenses continues to put bottom-line pressure. It also faces stiff competition. However, we are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within the company’s domestic market. The company is making efforts in product innovation through R&D investments. Treatment of the first patient in the Middle East with peripheral orbital atherectomy system was a vital highlight. The U.S. commercial launch of Viperwire Advance Coronary Guide Wire with Flex Tip instills optimism. The company exhibited a mixed performance with loss wider than estimates and revenues beating the consensus mark in first quarter. Over the past six months, the company outperformed the industry it belongs to." (1/13/2020)
- 2. Needham & Company LLC analysts commented, "CSII’s F3Q19 revenue and EPS beat consensus and management raised the lower end of its FY19 revenue guidance. Gross margin was down 130 bps and just offset 120 bps of operating leverage resulting in an operating margin of 0.8% that was down 10 bps Y/Y. Continued strength in CSII’s core atherectomy business and building momentum in its OEM and international businesses give us increased confidence in its ability to meet its FY19 revenue guidance but we see limited potential for meaningful upside and maintain our Hold rating." (5/2/2019)
Has Cardiovascular Systems been receiving favorable news coverage?
Press coverage about CSII stock has been trending very negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cardiovascular Systems earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Cardiovascular Systems.
Are investors shorting Cardiovascular Systems?
Cardiovascular Systems saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,770,000 shares, an increase of 9.9% from the January 15th total of 1,610,000 shares. Based on an average trading volume of 270,500 shares, the days-to-cover ratio is currently 6.5 days. Approximately 5.2% of the shares of the company are short sold. View Cardiovascular Systems' Current Options Chain.
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Varian Medical Systems (VAR) and Hologic (HOLX).
What other stocks do shareholders of Cardiovascular Systems own?
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 59)
- Mr. Jeffrey S. Points, Chief Financial Officer (Age 42)
- Ms. Rhonda J. Robb, Chief Operating Officer (Age 51)
- Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 47)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 58)
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by many different of retail and institutional investors. Top institutional investors include Champlain Investment Partners LLC (6.80%), Renaissance Technologies LLC (4.77%), State Street Corp (3.41%), New York State Common Retirement Fund (2.17%), Geode Capital Management LLC (1.58%) and Janus Henderson Group PLC (1.53%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Jeffrey S Points, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which major investors are selling Cardiovascular Systems stock?
CSII stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Falcon Point Capital LLC, Prudential Financial Inc., Russell Investments Group Ltd., PNC Financial Services Group Inc., Bank of New York Mellon Corp, Arizona State Retirement System and Sei Investments Co.. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein and Sandra Sedo. View Insider Buying and Selling for Cardiovascular Systems.
Which major investors are buying Cardiovascular Systems stock?
CSII stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Champlain Investment Partners LLC, Sectoral Asset Management Inc, Renaissance Technologies LLC, Madison Asset Management LLC, Bank of Montreal Can, Jacobs Levy Equity Management Inc. and Great West Life Assurance Co. Can. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $38.67.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $1.36 billion and generates $248.02 million in revenue each year. The medical device company earns $-250,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe.View Additional Information About Cardiovascular Systems.
What is Cardiovascular Systems' official website?
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
